Teva settlement prevents Lupin from launching its Austedo generic until 2033

Teva has high hopes for its tardive dyskinesia (TD) treatment Austedo. Now, the company has one less generic drugmaker to worry about as a threat to its core growth driver.

On Monday, Teva revealed that it has agreed to a settlement with Lupin that will allow the Mumbai-based generics manufacturer to sell its version of Austedo in the U.S. beginning in April 2033.